-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Daiichi Sankyo and AstraZeneca have jointly made breakthrough progress in ADC drug development.
Recently, Daiichi Sankyo collaborated with AstraZeneca on another Datopotamab deruxtecan, a specially designed TROP2-directed DXd antibody-drug conjugate (ADC)
The latest research results published on NSCLC are equally amazing!
Preliminary results from the TROPION-Lung02 Phase Ib trial show that datopotamab deruxtecan (Dato-DXd) with or without pembrolizumab in combination with platinum-based chemotherapy in previously untreated or pretreated, advanced or metastatic small cell lung cancer without treatable genomic alterations ( NSCLC)
An interim analysis of the ongoing TROPION-Lung02 trial showed an overall response rate (ORR) of 37% in patients treated with datopotamab deruxtecan and pembrolizumab (dual therapy) (median follow-up 6.
Further analysis revealed an ORR of 62% (8 of 13 patients) in the dual-therapy group and 50% (10 of 20 patients) in the triple-therapy group in previously untreated patients
Meanwhile, the combination of datopotamab deruxtecan showed a tolerable safety profile, which supports further evaluation in ongoing studies
In the dual cohort, patients had received a prior midline therapy consisting of platinum chemotherapy (60%) and immunotherapy (30%)
Benjamin Philip Levy, MD, clinical director of medical oncology at the Sidney Kimmel Cancer Center at the Johns Hopkins Memorial Hospital Sidney Kimmel Cancer Center, associate professor of oncology at the Johns Hopkins University School of Medicine, and investigator of the TROPION-Lung02 trial, said: "Many late-stage Disease progression in patients with non-small cell lung cancer after initial therapy underscores the need for new treatments.
Cristian Massacesi, Chief Medical Officer and Chief Development Officer, Oncology, AstraZeneca, said: "Based on the preliminary results of the datopotamab deruxtecan combination in triple-negative breast cancer shared earlier this year, these preliminary results from TROPION-Lung02 reflect the improved combination of the combination therapy.
